CMS CY2027 Final Rule: What Medicare Advantage Plans Should Do in 2026
The April 2026 Final Rule is the most consequential MA regulatory change since 2023. Most structural changes hit 2029 ratings — but the operational work starts now.
- The 2027 Star Ratings impact is modest: four measures added, three removed, with eye exam for diabetics retained after plan objections.
- The bigger story is 2029: weight rebalancing toward clinical outcomes and member experience will reshape competitive positioning, with CAHPS and HOS approaching 40% of total Star weight.
- Health equity requirements were rolled back: MA plans no longer must include health disparity reduction in QI programs — but plans serving dual-eligible and underserved populations should sustain these activities anyway.
- The MTM CMR completion measure is gone — pharmacy ops teams that built infrastructure around this should redirect those resources to the new opioid/benzodiazepine and polypharmacy measures.
- 2026 is the operational planning year. Plans that wait until 2027 to adapt will lose two full performance periods of advantage on 2029 ratings.
The CMS CY2027 Medicare Advantage and Part D Final Rule, published in April 2026, is being read in two very different ways across the industry. Optimists see a relatively contained 2027 Star Ratings update — a handful of measure changes and a politically expected health equity rollback. Pessimists see the structural foundation for a 2029 rating system that will look meaningfully different from today's, with substantially more weight on clinical outcomes and member experience. Both readings are correct. Both also miss the more urgent point: the operational decisions that will determine 2029 outcomes are being made in 2026, not 2028.
This piece walks through what changed, what it means by function, and a concrete checklist for what Medicare Advantage plans should be doing right now.
What Changed for 2027 Star Ratings
The 2027 ratings — based on CY2025 measurement year data, which is already in the books — see four new measures added, three removed, and one notable retention.
Measures Added for 2027
| Measure | Why It Was Added |
|---|---|
| Colorectal Cancer Screening (respecified) | Aligns with updated USPSTF guidance and HEDIS specifications. Plans that have already optimized CRC screening pathways will have minimal new work; those that haven't will see scoring volatility. |
| Care for Older Adults — Functional Status Assessment | Reflects CMS's continued push toward measuring whether older adults are actually doing well, not just whether they got a screening. This measure has historically been hard to score on consistently. |
| Concurrent Use of Opioids and Benzodiazepines | Direct response to ongoing opioid stewardship priorities. Pharmacy and care management teams need clear concurrent-use detection workflows. |
| Polypharmacy / Anticholinergic Medications in Older Adults | Adds pharmacological complexity to the geriatric measure set. Plans without strong med-rec workflows will see this measure suffer first. |
Measures Removed for 2027
Three measures are out, including the politically and operationally significant MTM CMR Completion Rate. For plans that built dedicated infrastructure around CMR completion — outreach scripting, pharmacist workflow tools, member incentive programs — this is a real shift. The investments don't disappear, but they can be redirected toward the two new pharmacy-related measures (opioid/benzo, polypharmacy), which need similar pharmacist-led workflows.
The Eye Exam Retention
CMS proposed removing the diabetic retinal eye exam measure but reversed course in the final rule after sustained plan objections. This is worth noting strategically: it confirms that organized plan feedback during the comment period continues to influence final rules. Plans should treat the next NPRM cycle as a real input opportunity, not a formality.
The Bigger Story: 2029 Ratings
The headline-friendly changes are the 2027 measure swaps. The strategically meaningful changes are the structural shifts that take effect in the 2027 measurement period — meaning they'll inform 2029 Star Ratings, not 2027's. Two changes stand out.
Weight Shifts Toward Clinical Outcomes
CMS is continuing to rebalance domain weights to emphasize outcomes over process measures. Plans that have over-invested in process measure optimization (gap closure campaigns, screening throughput) at the expense of outcome quality (HEDIS controlling-high-blood-pressure-style measures, readmission rates) will see their relative position erode through 2029.
Member Experience Approaching 40%
By 2029, CAHPS and HOS combined will represent close to 40% of total Star weight. The plans that win 2029 will be the plans that started taking member experience seriously in 2026.
This is the change most plans are still under-weighting. CAHPS surveys run February through March; HOS runs June through July. The behaviors that drive those scores — call center experience, ease of getting appointments, perceived care coordination — are the product of operational investments made 12-18 months earlier. Plans that wait until late 2027 to start improving member experience will already be too late for 2029.
Health Equity Requirements: What Was Rolled Back
The Final Rule removes the requirement that MA plans include health disparity reduction activities in their quality improvement programs. This was the headline DEI rollback, and it's real. But the practical implications are nuanced.
Plans that primarily serve commercial-adjacent MA populations may genuinely be able to sunset disparity-reduction activities without operational consequences. Plans that serve D-SNPs, dual-eligibles, or socioeconomically diverse markets should think carefully before doing so. The reasons:
- State Medicaid contracts often require disparity work. If you have a D-SNP, your MIPPA contract or state oversight likely still demands it. The federal rollback doesn't override state requirements.
- Disparity reduction activities are quality interventions in disguise. Many of the things plans were doing under "health equity" — language access, transportation support, culturally adapted outreach — directly drive HEDIS and Stars performance in mixed populations. Stopping them costs measurable performance.
- Future regulatory whiplash is plausible. Tearing down infrastructure that you may need to rebuild within 24-36 months is operationally expensive. Maintaining capabilities at a baseline level is the conservative play.
If your plan serves any meaningful share of dual-eligible or underserved members, treat the federal rollback as a permission slip to scope down — not as a directive to dismantle. Reframe disparity reduction work as targeted quality improvement and protect the operational capabilities. The plans that strip these capabilities for cost savings will likely rebuild them at higher cost within two years.
Operational Implications by Function
Quality / Stars Team
- Build measurement infrastructure for the four new 2027 measures now — don't wait for 2027 measurement year to begin.
- Sunset MTM CMR-specific reporting and redirect those resources toward the new pharmacy measures.
- Begin 2029 strategic planning: model what your Star Rating would look like under the new weight structure with current performance, then identify the largest gaps.
Risk Adjustment / RAF Team
- The Final Rule does not significantly change V28 transition or RAF calculation methodology, but the parallel 2027 Advance Notice continues the V28 phase-in.
- Coordinate with Quality on shared measure pulls (Care for Older Adults, polypharmacy) — these measures rely on the same encounter data that drives RAF accuracy. Integrated workflows pay off twice.
Member Experience
- Member experience is now the highest-leverage Stars investment available. Audit your call center, appointment access, and care coordination experience — not at the policy level, but at the actual member-touched-it level.
- Plan CAHPS and HOS interventions for early 2027 deployment to influence 2029 ratings.
Compliance
- Update QI program documentation to reflect the rollback of the health equity requirement, but preserve documentation of voluntary disparity reduction activities tied to D-SNP or state contract requirements.
- Track the 2027 NPRM cycle closely — the next round of changes will likely be more, not less, consequential.
The 2026 Action Checklist
Concrete actions for the remainder of 2026:
| Timing | Action |
|---|---|
| Q2 2026 | Complete impact assessment for the four new 2027 measures. Identify which measure is your weakest, model spend required to move it. |
| Q2 2026 | Decide explicitly: which health equity activities continue, which sunset, which transition to "voluntary quality improvement" framing. |
| Q3 2026 | Stand up measurement infrastructure for the new pharmacy measures (concurrent opioid/benzo, polypharmacy). Don't reuse MTM CMR workflows wholesale — these measures behave differently. |
| Q3 2026 | Run a 2029 Star Rating projection under the new weight structure. Identify the top three intervention areas. |
| Q4 2026 | Build the member experience improvement plan for early-2027 deployment. CAHPS interventions launched in Q1 2027 inform 2029 ratings. |
| Q4 2026 | Submit comments on the next NPRM. Plans that engage shape the rules. |
The Strategic Punchline
The CY2027 Final Rule is being widely read as a relatively quiet regulatory cycle. That reading is wrong in one specific way: 2026 is when the work for 2029 happens. The plans that wait to act until 2027 measurement year begins will have already lost a year of compounding performance gains. The plans that begin operationalizing now — particularly on member experience and the new measures — will build advantage that's very hard to close in twelve months.
The good news: this is one of the more legible Final Rules in recent memory. The changes are clear, the timelines are reasonable, and the operational playbook is more straightforward than the 2024 risk adjustment overhaul. The plans that take action systematically rather than reactively will be the ones whose 2029 ratings reward 2026 decisions.
Want a 30-minute walkthrough of how the CY2027 Final Rule affects your plan specifically? IQRP can model your 2029 Star Rating projection and identify the top three intervention areas.
Request a Consultation →